{
    "id": 5110,
    "date": "2026-07-20T13:34:40",
    "date_gmt": "2026-07-20T11:34:40",
    "guid": {
        "rendered": "https:\/\/www.phinc-group.com\/?p=5110"
    },
    "modified": "2026-07-27T11:17:00",
    "modified_gmt": "2026-07-27T09:17:00",
    "slug": "avoiding-late-stage-failure-in-oncology",
    "status": "publish",
    "type": "post",
    "link": "https:\/\/www.phinc-group.com\/fr\/avoiding-late-stage-failure-in-oncology\/",
    "title": {
        "rendered": "Eviter les \u00e9checs de stade avanc\u00e9 en oncologie"
    },
    "content": {
        "rendered": "<div data-elementor-type=\"wp-post\" data-elementor-id=\"5110\" class=\"elementor elementor-5110\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f1d91ef e-con-full e-flex e-con e-parent\" data-id=\"f1d91ef\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7c165e5 elementor-widget elementor-widget-html\" data-id=\"7c165e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"midd-page\">\r\n  <style>\r\n    @import url('https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;1,300;1,400&family=Poppins:wght@200;300;400;600;700&display=swap');\r\n\r\n    .midd-page {\r\n      --phinc-blue: #00005f;\r\n      --phinc-pink: #d94b9f;\r\n      --ink: #0F172A;\r\n      --muted: #475569;\r\n      --line: #E6EAF2;\r\n      --bg: #F7F9FC;\r\n      --card: #FFFFFF;\r\n      --radius: 18px;\r\n      --shadow: 0 10px 30px rgba(15, 23, 42, .08);\r\n      --max: 860px;\r\n      --max-wide: 1100px;\r\n\r\n      font-family: 'Poppins', sans-serif;\r\n      color: var(--ink);\r\n      background: #fff;\r\n      line-height: 1.65;\r\n    }\r\n    .midd-page, .midd-page *, .midd-page *::before, .midd-page *::after {\r\n      box-sizing: border-box;\r\n    }\r\n\r\n    \/* \u2500\u2500 HERO \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-hero {\r\n      background:\r\n        radial-gradient(1100px 500px at 5% 0%, rgba(0,0,95,.13), transparent 55%),\r\n        radial-gradient(800px 400px at 95% 10%, rgba(217,75,159,.12), transparent 50%),\r\n        linear-gradient(180deg, #ffffff 0%, var(--bg) 100%);\r\n      border-bottom: 1px solid var(--line);\r\n      padding: 80px 20px 60px;\r\n    }\r\n    .midd-page .midd-hero-inner { max-width: var(--max-wide); margin: 0 auto; }\r\n\r\n    .midd-page .midd-eyebrow {\r\n      display: inline-flex; align-items: center; gap: 10px;\r\n      padding: 7px 14px; border: 1px solid var(--line); border-radius: 999px;\r\n      font-size: 12px; font-weight: 400; color: var(--muted); background: #fff;\r\n      margin-bottom: 22px; letter-spacing: .04em; text-transform: uppercase;\r\n    }\r\n    .midd-page .midd-eyebrow-dot {\r\n      width: 8px; height: 8px; border-radius: 999px;\r\n      background: linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n      flex: 0 0 auto;\r\n    }\r\n\r\n    .midd-page .midd-hero-grid {\r\n      display: grid; grid-template-columns: 1fr 1fr; gap: 48px; align-items: center;\r\n    }\r\n    .midd-page .midd-hero h1 {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 52px; font-weight: 300;\r\n      line-height: 1.08; letter-spacing: -.02em; margin-bottom: 20px;\r\n    }\r\n    .midd-page .midd-hero h1 em { font-style: normal; color: var(--phinc-pink); }\r\n    .midd-page .midd-meta { display: flex; align-items: center; gap: 20px; flex-wrap: wrap; }\r\n    .midd-page .midd-meta-pill {\r\n      font-size: 12px; padding: 6px 12px; border: 1px solid var(--line);\r\n      border-radius: 999px; color: var(--muted); background: #fff;\r\n    }\r\n\r\n    \/* \u2500\u2500 HERO IMAGE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-hero-visual {\r\n      width: 100%; aspect-ratio: 4\/3; border-radius: var(--radius);\r\n      border: 1px solid var(--line); box-shadow: var(--shadow);\r\n      position: relative; overflow: hidden; background: var(--bg);\r\n      background-size: cover; background-position: center;\r\n    }\r\n\r\n    \/* \u2500\u2500 ARTICLE BODY \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-body { max-width: var(--max); margin: 0 auto; padding: 64px 20px; }\r\n\r\n    .midd-page .midd-intro {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 26px; font-weight: 300;\r\n      line-height: 1.45; color: var(--ink); border-left: 3px solid var(--phinc-pink);\r\n      padding-left: 24px; margin-bottom: 40px;\r\n    }\r\n\r\n    .midd-page .midd-section-title {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 36px; font-weight: 300;\r\n      line-height: 1.12; letter-spacing: -.01em; margin-bottom: 18px; color: var(--ink);\r\n    }\r\n    .midd-page .midd-section-title em { font-style: normal; color: var(--phinc-pink); }\r\n\r\n    .midd-page .midd-p {\r\n      font-size: 16px; font-weight: 300; color: var(--muted); line-height: 1.75; margin-bottom: 20px;\r\n    }\r\n    .midd-page .midd-p strong { font-weight: 600; color: var(--ink); }\r\n\r\n    \/* \u2500\u2500 VERBATIM BULLET LIST \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-list {\r\n      list-style: none; margin: 0 0 20px 0; padding: 0;\r\n      display: grid; gap: 14px;\r\n    }\r\n    .midd-page .midd-list li {\r\n      display: flex; gap: 14px; align-items: flex-start;\r\n      background: var(--card); border: 1px solid var(--line); border-radius: var(--radius);\r\n      padding: 20px 22px; font-size: 15px; font-weight: 300; color: var(--muted); line-height: 1.6;\r\n      box-shadow: 0 4px 16px rgba(15,23,42,.04);\r\n    }\r\n    .midd-page .midd-list li::before {\r\n      content: ''; width: 8px; height: 8px; border-radius: 999px; margin-top: 7px; flex: 0 0 auto;\r\n      background: linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n    }\r\n\r\n    \/* \u2500\u2500 STAT ROW (termes\/chiffres du texte) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-stat-row {\r\n      display: grid; grid-template-columns: repeat(3, 1fr); gap: 16px; margin: 8px 0 36px;\r\n    }\r\n    .midd-page .midd-stat {\r\n      background: var(--bg); border: 1px solid var(--line); border-radius: var(--radius);\r\n      padding: 22px 18px; text-align: center;\r\n    }\r\n    .midd-page .midd-stat-number {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 44px; font-weight: 300;\r\n      line-height: 1; color: var(--phinc-blue); margin-bottom: 6px;\r\n    }\r\n    .midd-page .midd-stat-number span { color: var(--phinc-pink); }\r\n    .midd-page .midd-stat-label { font-size: 12.5px; font-weight: 300; color: var(--muted); line-height: 1.4; }\r\n\r\n    \/* \u2500\u2500 PULL QUOTE (phrase verbatim du texte) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-quote {\r\n      background: linear-gradient(135deg, rgba(0,0,95,.05), rgba(217,75,159,.07));\r\n      border: 1px solid var(--line); border-radius: var(--radius);\r\n      padding: 32px 36px; margin: 40px 0; position: relative;\r\n    }\r\n    .midd-page .midd-quote::before {\r\n      content: '\"'; font-family: 'Cormorant Garamond', serif; font-size: 100px; line-height: .7;\r\n      color: var(--phinc-pink); opacity: .25; position: absolute; top: 20px; left: 24px;\r\n      pointer-events: none;\r\n    }\r\n    .midd-page .midd-quote p {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 21px; font-weight: 300;\r\n      font-style: italic; line-height: 1.5; color: var(--ink); position: relative; z-index: 1;\r\n    }\r\n\r\n    \/* \u2500\u2500 IMAGE BANNI\u00c8RE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-image-placeholder {\r\n      width: 100%; aspect-ratio: 21\/7; border-radius: var(--radius); border: 1px solid var(--line);\r\n      background: var(--bg); background-size: cover; background-position: center; margin: 40px 0;\r\n    }\r\n\r\n    \/* \u2500\u2500 CLOSING CTA \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-cta-block {\r\n      background: linear-gradient(135deg, var(--phinc-blue) 0%, #00008a 60%, #3d0050 100%);\r\n      border-radius: var(--radius); padding: 52px 48px; text-align: center; margin-top: 48px;\r\n      position: relative; overflow: hidden;\r\n    }\r\n    .midd-page .midd-cta-block::before {\r\n      content: ''; position: absolute; inset: 0;\r\n      background: radial-gradient(600px 400px at 80% 120%, rgba(217,75,159,.3), transparent 60%);\r\n      pointer-events: none;\r\n    }\r\n    .midd-page .midd-cta-block h2 {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 38px; font-weight: 300; color: #fff;\r\n      margin-bottom: 14px; position: relative;\r\n    }\r\n    .midd-page .midd-cta-block h2 em { font-style: italic; color: #f9b8e4; }\r\n    .midd-page .midd-cta-block p {\r\n      font-size: 15.5px; font-weight: 300; color: rgba(255,255,255,.7); max-width: 520px;\r\n      margin: 0 auto 28px; line-height: 1.6; position: relative;\r\n    }\r\n    .midd-page .midd-btn {\r\n      display: inline-flex; align-items: center; gap: 10px; padding: 15px 28px;\r\n      border-radius: 12px; text-decoration: none; font-weight: 600; font-size: 15px;\r\n      position: relative; cursor: pointer; transition: transform .12s ease, box-shadow .12s ease;\r\n    }\r\n    .midd-page .midd-btn:hover { transform: translateY(-2px); }\r\n    .midd-page .midd-btn.primary {\r\n      background: var(--phinc-pink); color: #fff; border: none; box-shadow: 0 8px 24px rgba(217,75,159,.4);\r\n    }\r\n    .midd-page .midd-btn.ghost {\r\n      background: rgba(255,255,255,.12); color: #fff; border: 1px solid rgba(255,255,255,.25);\r\n      backdrop-filter: blur(4px);\r\n    }\r\n    .midd-page .midd-cta-actions { display: flex; justify-content: center; gap: 14px; flex-wrap: wrap; }\r\n\r\n    \/* \u2500\u2500 DIVIDER \/ REFERENCES \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .midd-page .midd-divider { height: 1px; background: var(--line); margin: 48px 0; }\r\n    .midd-page .midd-refs h3 {\r\n      font-family: 'Cormorant Garamond', serif; font-size: 22px; font-weight: 300;\r\n      color: var(--ink); margin-bottom: 14px;\r\n    }\r\n    .midd-page .midd-refs ol { padding-left: 20px; font-size: 12.5px; color: var(--muted); font-weight: 300; }\r\n    .midd-page .midd-refs li { margin-bottom: 8px; }\r\n\r\n    @media (max-width: 780px) {\r\n      .midd-page .midd-hero-grid { grid-template-columns: 1fr; gap: 28px; }\r\n      .midd-page .midd-hero h1 { font-size: 36px; }\r\n      .midd-page .midd-section-title { font-size: 28px; }\r\n      .midd-page .midd-stat-row { grid-template-columns: 1fr; }\r\n      .midd-page .midd-cta-block { padding: 36px 24px; }\r\n      .midd-page .midd-cta-block h2 { font-size: 30px; }\r\n    }\r\n  <\/style>\r\n\r\n  <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 HERO \u2550\u2550\u2550 -->\r\n  <header class=\"midd-hero\">\r\n    <div class=\"midd-hero-inner\">\r\n      <div class=\"midd-eyebrow\">\r\n        <span class=\"midd-eyebrow-dot\"><\/span>\r\n        Model-Informed Drug Development\r\n      <\/div>\r\n      <div class=\"midd-hero-grid\">\r\n        <div>\r\n          <h1>\u00c9viter les \u00e9checs de stade avanc\u00e9 en oncologie <em>gr\u00e2ce au MIDD<\/em><\/h1>\r\n          <div class=\"midd-meta\">\r\n            <span class=\"midd-meta-pill\">MIDD<\/span>\r\n            <span class=\"midd-meta-pill\">Oncologie<\/span>\r\n            <span class=\"midd-meta-pill\">Phase III<\/span>\r\n          <\/div>\r\n        <\/div>\r\n\r\n        <!-- \ud83d\udcf8 EMPLACEMENT PHOTO \u2014 HERO (image int\u00e9gr\u00e9e) -->\r\n        <div class=\"midd-hero-visual\" aria-label=\"Image principale oncologie\"\r\n             style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png');\"><\/div>\r\n      <\/div>\r\n    <\/div>\r\n  <\/header>\r\n\r\n  <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 BODY \u2550\u2550\u2550 -->\r\n  <article class=\"midd-body\">\r\n\r\n    <p class=\"midd-intro\">\r\n      L'attrition aux stades avanc\u00e9s du d\u00e9veloppement de m\u00e9dicaments en oncologie repr\u00e9sente une inefficacit\u00e9 scientifique et \u00e9conomique substantielle, avec des taux d'\u00e9chec en phase III d\u00e9passant souvent 50&nbsp;%<sup>[1]<\/sup>.\r\n    <\/p>\r\n\r\n    <p class=\"midd-p\">\r\n      Bien que les essais de phase pr\u00e9coce puissent donner des signaux initiaux prometteurs, ces r\u00e9sultats ne se traduisent fr\u00e9quemment pas dans des populations de patients plus larges et h\u00e9t\u00e9rog\u00e8nes.\r\n    <\/p>\r\n\r\n    <p class=\"midd-p\">\r\n      La d\u00e9pendance traditionnelle \u00e0 l'extrapolation empirique de la phase II \u00e0 la phase III est de plus en plus reconnue comme insuffisante. Cela a provoqu\u00e9 un changement de paradigme vers des m\u00e9thodologies quantitatives, s'alignant sur les attentes r\u00e9glementaires et des principes similaires \u00e0 ceux discut\u00e9s dans le FDA MIDD Paired Pilot Program<sup>[2]<\/sup>.\r\n    <\/p>\r\n\r\n    <div class=\"midd-stat-row\">\r\n      <div class=\"midd-stat\">\r\n        <div class=\"midd-stat-number\"><span>&gt;50%<\/span><\/div>\r\n        <div class=\"midd-stat-label\">de taux d'\u00e9chec en phase III<\/div>\r\n      <\/div>\r\n      <div class=\"midd-stat\">\r\n        <div class=\"midd-stat-number\">PTS<\/div>\r\n        <div class=\"midd-stat-label\">probabilit\u00e9 de succ\u00e8s technique<\/div>\r\n      <\/div>\r\n      <div class=\"midd-stat\">\r\n        <div class=\"midd-stat-number\">CTS<\/div>\r\n        <div class=\"midd-stat-label\">simulation d'essais cliniques<\/div>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <h2 class=\"midd-section-title\">\u00c9tiologie de l'attrition en phase III<\/h2>\r\n\r\n    <p class=\"midd-p\">\r\n      Le taux d'\u00e9chec \u00e9lev\u00e9 dans les essais pivots en oncologie d\u00e9coule de complexit\u00e9s biologiques et statistiques multifactorielles. Les principaux facteurs contribuant \u00e0 l'attrition \u00e0 un stade avanc\u00e9 comprennent&nbsp;:\r\n    <\/p>\r\n\r\n    <ul class=\"midd-list\">\r\n      <li>Une s\u00e9lection sous-optimale de la dose entra\u00eenant une efficacit\u00e9 marginale ou des profils de toxicit\u00e9 intol\u00e9rables<sup>[3]<\/sup>.<\/li>\r\n      <li>Une surestimation des tailles d'effet du traitement d\u00e9riv\u00e9es de cohortes de phase pr\u00e9coce homog\u00e8nes et sous-dimensionn\u00e9es<sup>[4]<\/sup>.<\/li>\r\n      <li>Une stratification inad\u00e9quate des patients et une d\u00e9pendance excessive \u00e0 des biomarqueurs pr\u00e9dictifs non valid\u00e9s<sup>[5]<\/sup>.<\/li>\r\n      <li>Une puissance statistique insuffisante pour d\u00e9tecter des diff\u00e9rences cliniquement significatives par rapport aux comparateurs de la norme de soins en \u00e9volution<sup>[1]<\/sup>.<\/li>\r\n    <\/ul>\r\n\r\n    <div class=\"midd-divider\"><\/div>\r\n\r\n    <h2 class=\"midd-section-title\">Le r\u00f4le du d\u00e9veloppement de m\u00e9dicaments inform\u00e9 par la mod\u00e9lisation (<em>MIDD<\/em>)<\/h2>\r\n\r\n    <p class=\"midd-p\">\r\n      Le d\u00e9veloppement de m\u00e9dicaments inform\u00e9 par la mod\u00e9lisation (MIDD) sert de cadre quantitatif critique pour att\u00e9nuer ces risques de stade avanc\u00e9. En int\u00e9grant la pharmacocin\u00e9tique (PK), la pharmacodynamique (PD), la mod\u00e9lisation de la progression de la maladie et les donn\u00e9es d'essais historiques, le MIDD permet aux d\u00e9veloppeurs d'\u00e9valuer syst\u00e9matiquement les hypoth\u00e8ses scientifiques avant d'initier des essais \u00e0 grande \u00e9chelle<sup>[6]<\/sup>.\r\n    <\/p>\r\n\r\n    <p class=\"midd-p\">\r\n      Au lieu de s'appuyer strictement sur des donn\u00e9es d'observation issues de cohortes pr\u00e9coces, le MIDD facilite le calcul de la probabilit\u00e9 de succ\u00e8s technique (PTS) \u00e0 travers diverses conceptions d'essais, doses et populations de patients<sup>[7]<\/sup>.\r\n    <\/p>\r\n\r\n    <!-- \ud83d\udcf8 EMPLACEMENT PHOTO \u2014 banni\u00e8re large (image int\u00e9gr\u00e9e) -->\r\n    <div class=\"midd-image-placeholder\" aria-label=\"Image banni\u00e8re MIDD \/ simulation d'essais cliniques\"\r\n         style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/banner-late-stage-in-oncology-1800x600-1.png');\"><\/div>\r\n\r\n    <h2 class=\"midd-section-title\">R\u00e9duction des risques via la simulation d'essais cliniques (<em>CTS<\/em>)<\/h2>\r\n\r\n    <p class=\"midd-p\">\r\n      Une application fondamentale du MIDD dans le d\u00e9veloppement \u00e0 un stade avanc\u00e9 est la simulation d'essais cliniques (CTS). La CTS permet l'ex\u00e9cution in silico d'essais pivots sous divers sc\u00e9narios, g\u00e9n\u00e9rant des preuves quantitatives solides pour soutenir les d\u00e9cisions de transition.\r\n    <\/p>\r\n\r\n    <p class=\"midd-p\">Plus pr\u00e9cis\u00e9ment, la CTS soutient&nbsp;:<\/p>\r\n\r\n    <ul class=\"midd-list\">\r\n      <li>La mod\u00e9lisation exposition-r\u00e9ponse (E-R) pour justifier la s\u00e9lection de la dose pivot et optimiser les indices th\u00e9rapeutiques<sup>[3]<\/sup>.<\/li>\r\n      <li>L'optimisation des tailles d'\u00e9chantillon et des dur\u00e9es d'essai pour garantir une puissance statistique ad\u00e9quate<sup>[6]<\/sup>.<\/li>\r\n      <li>Les strat\u00e9gies d'enrichissement bas\u00e9es sur les biomarqueurs pour d\u00e9finir les sous-populations de r\u00e9pondeurs optimales<sup>[5]<\/sup>.<\/li>\r\n      <li>L'\u00e9valuation de conceptions d'essais adaptatives pour int\u00e9grer des analyses interm\u00e9diaires et minimiser le risque clinique<sup>[7]<\/sup>.<\/li>\r\n    <\/ul>\r\n\r\n    <div class=\"midd-divider\"><\/div>\r\n\r\n    <h2 class=\"midd-section-title\">Implications strat\u00e9giques et r\u00e9glementaires<\/h2>\r\n\r\n    <p class=\"midd-p\">\r\n      Au-del\u00e0 de l'att\u00e9nuation des risques, le MIDD am\u00e9liore la valeur strat\u00e9gique des actifs cliniques. Les conceptions optimis\u00e9es de phase III produisent des dossiers de preuves plus solides, de plus en plus attendus par les agences r\u00e9glementaires mondiales<sup>[8]<\/sup>.\r\n    <\/p>\r\n\r\n    <p class=\"midd-p\">\r\n      L'int\u00e9gration de la mod\u00e9lisation quantitative s'aligne sur les initiatives r\u00e9glementaires contemporaines visant \u00e0 r\u00e9duire les d\u00e9lais de d\u00e9veloppement, \u00e0 optimiser l'allocation des ressources et \u00e0 garantir que les th\u00e9rapies offrent un b\u00e9n\u00e9fice clinique maximal<sup>[2]<\/sup>.\r\n    <\/p>\r\n\r\n    <div class=\"midd-quote\">\r\n      <p>Le paysage du d\u00e9veloppement en oncologie passe d'une expansion clinique empirique \u00e0 un stade avanc\u00e9 \u00e0 une ex\u00e9cution d'essais pr\u00e9dictive et ax\u00e9e sur des mod\u00e8les.<\/p>\r\n    <\/div>\r\n\r\n    <p class=\"midd-p\">\r\n      L'int\u00e9gration solide du MIDD avant le lancement de la phase III est essentielle pour \u00e9viter les \u00e9checs \u00e0 un stade avanc\u00e9 et \u00e9tablir une voie statistiquement fiable vers l'approbation r\u00e9glementaire<sup>[8]<\/sup>.\r\n    <\/p>\r\n\r\n    <!-- \u2500\u2500 CTA DE CL\u00d4TURE (UI\/marketing, hors contenu scientifique) \u2500\u2500 -->\r\n    <div class=\"midd-cta-block\">\r\n      <h2>Discutons de votre <em>strat\u00e9gie MIDD<\/em> en oncologie<\/h2>\r\n      <p>\r\n        Partagez votre stade de d\u00e9veloppement et vos donn\u00e9es disponibles. Notre \u00e9quipe vous propose une approche MIDD adapt\u00e9e \u00e0 votre programme.\r\n      <\/p>\r\n      <div class=\"midd-cta-actions\">\r\n        <a class=\"midd-btn primary\" href=\"\/fr\/contact\/\">Planifier un \u00e9change<\/a>\r\n        <a class=\"midd-btn ghost\" href=\"\/fr\/midd\/\">D\u00e9couvrir notre offre MIDD<\/a>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <div class=\"midd-divider\"><\/div>\r\n\r\n    <!-- \u2500\u2500 R\u00c9F\u00c9RENCES \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"midd-refs\">\r\n      <h3>R\u00e9f\u00e9rences<\/h3>\r\n      <ol>\r\n        <li>Wong, C. H., Siah, K. W., &amp; Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. <em>Biostatistics<\/em>, 20(2), 273-286.<\/li>\r\n        <li>FDA (2018). Model-Informed Drug Development Pilot Program. U.S. Food and Drug Administration.<\/li>\r\n        <li>Shah, D. K., et al. (2012). Model-based drug development of oncology therapeutic antibodies. <em>Journal of Pharmacokinetics and Pharmacodynamics<\/em>, 39(5), 453-469.<\/li>\r\n        <li>Hwang, T. J., et al. (2016). Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. <em>JAMA Internal Medicine<\/em>, 176(12), 1826-1833.<\/li>\r\n        <li>Milligan, P. A., et al. (2013). Model-based drug development: a rational approach to efficiently accelerate drug development. <em>Clinical Pharmacology &amp; Therapeutics<\/em>, 93(6), 502-514.<\/li>\r\n        <li>Marshall, S. F., et al. (2016). Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations. <em>CPT: Pharmacometrics &amp; Systems Pharmacology<\/em>, 5(2), 55-63.<\/li>\r\n        <li>Lalonde, R. L., et al. (2007). Model-based drug development. <em>Clinical Pharmacology &amp; Therapeutics<\/em>, 82(1), 21-32.<\/li>\r\n        <li>Zineh, I. (2019). Quantitative Pharmacology and Model-Informed Drug Development in the Regulatory Setting. <em>The Journal of Clinical Pharmacology<\/em>, 59(S1), S5-S8.<\/li>\r\n      <\/ol>\r\n    <\/div>\r\n\r\n  <\/article>\r\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>",
        "protected": false
    },
    "excerpt": {
        "rendered": "<p>L&rsquo;attrition aux stades avanc\u00e9s du d\u00e9veloppement de m\u00e9dicaments en oncologie repr\u00e9sente une inefficacit\u00e9 scientifique et \u00e9conomique substantielle, avec des taux d&rsquo;\u00e9chec en phase III d\u00e9passant souvent 50%.<\/p>",
        "protected": false
    },
    "author": 2,
    "featured_media": 5109,
    "comment_status": "closed",
    "ping_status": "closed",
    "sticky": false,
    "template": "elementor_header_footer",
    "format": "standard",
    "meta": {
        "_acf_changed": false,
        "footnotes": ""
    },
    "categories": [
        37
    ],
    "tags": [],
    "service-associe": [],
    "class_list": [
        "post-5110",
        "post",
        "type-post",
        "status-publish",
        "format-standard",
        "has-post-thumbnail",
        "hentry",
        "category-blog"
    ],
    "acf": [],
    "yoast_head": "<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eviter les \u00e9checs de stade avanc\u00e9 en oncologie - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/fr\/avoiding-late-stage-failure-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eviter les \u00e9checs de stade avanc\u00e9 en oncologie - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"L&#039;attrition aux stades avanc\u00e9s du d\u00e9veloppement de m\u00e9dicaments en oncologie repr\u00e9sente une inefficacit\u00e9 scientifique et \u00e9conomique substantielle, avec des taux d&#039;\u00e9chec en phase III d\u00e9passant souvent 50%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/fr\/avoiding-late-stage-failure-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T11:34:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-27T09:17:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1448\" \/>\n\t<meta property=\"og:image:height\" content=\"1086\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"Eviter les \u00e9checs de stade avanc\u00e9 en oncologie\",\"datePublished\":\"2026-07-20T11:34:40+00:00\",\"dateModified\":\"2026-07-27T09:17:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/\"},\"wordCount\":908,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/late-stage-failure-in-oncology-4-3-ratio.png\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/\",\"name\":\"Eviter les \u00e9checs de stade avanc\u00e9 en oncologie - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/late-stage-failure-in-oncology-4-3-ratio.png\",\"datePublished\":\"2026-07-20T11:34:40+00:00\",\"dateModified\":\"2026-07-27T09:17:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/late-stage-failure-in-oncology-4-3-ratio.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/late-stage-failure-in-oncology-4-3-ratio.png\",\"width\":1448,\"height\":1086},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/avoiding-late-stage-failure-in-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eviter les \u00e9checs de stade avanc\u00e9 en oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions &amp; Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->",
    "yoast_head_json": {
        "title": "Eviter les \u00e9checs de stade avanc\u00e9 en oncologie - PhinC Group",
        "robots": {
            "index": "index",
            "follow": "follow",
            "max-snippet": "max-snippet:-1",
            "max-image-preview": "max-image-preview:large",
            "max-video-preview": "max-video-preview:-1"
        },
        "canonical": "https:\/\/www.phinc-group.com\/fr\/avoiding-late-stage-failure-in-oncology\/",
        "og_locale": "fr_FR",
        "og_type": "article",
        "og_title": "Eviter les \u00e9checs de stade avanc\u00e9 en oncologie - PhinC Group",
        "og_description": "L'attrition aux stades avanc\u00e9s du d\u00e9veloppement de m\u00e9dicaments en oncologie repr\u00e9sente une inefficacit\u00e9 scientifique et \u00e9conomique substantielle, avec des taux d'\u00e9chec en phase III d\u00e9passant souvent 50%.",
        "og_url": "https:\/\/www.phinc-group.com\/fr\/avoiding-late-stage-failure-in-oncology\/",
        "og_site_name": "PhinC Group",
        "article_published_time": "2026-07-20T11:34:40+00:00",
        "article_modified_time": "2026-07-27T09:17:00+00:00",
        "og_image": [
            {
                "width": 1448,
                "height": 1086,
                "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png",
                "type": "image\/png"
            }
        ],
        "author": "Mohamed Taourirt",
        "twitter_card": "summary_large_image",
        "twitter_misc": {
            "\u00c9crit par": "Mohamed Taourirt",
            "Dur\u00e9e de lecture estim\u00e9e": "5 minutes"
        },
        "schema": {
            "@context": "https:\/\/schema.org",
            "@graph": [
                {
                    "@type": "Article",
                    "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#article",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/"
                    },
                    "author": {
                        "name": "Mohamed Taourirt",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"
                    },
                    "headline": "Eviter les \u00e9checs de stade avanc\u00e9 en oncologie",
                    "datePublished": "2026-07-20T11:34:40+00:00",
                    "dateModified": "2026-07-27T09:17:00+00:00",
                    "mainEntityOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/"
                    },
                    "wordCount": 908,
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png",
                    "articleSection": [
                        "Blog"
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "WebPage",
                    "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/",
                    "url": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/",
                    "name": "Eviter les \u00e9checs de stade avanc\u00e9 en oncologie - PhinC Group",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#website"
                    },
                    "primaryImageOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#primaryimage"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png",
                    "datePublished": "2026-07-20T11:34:40+00:00",
                    "dateModified": "2026-07-27T09:17:00+00:00",
                    "breadcrumb": {
                        "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#breadcrumb"
                    },
                    "inLanguage": "fr-FR",
                    "potentialAction": [
                        {
                            "@type": "ReadAction",
                            "target": [
                                "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/"
                            ]
                        }
                    ]
                },
                {
                    "@type": "ImageObject",
                    "inLanguage": "fr-FR",
                    "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#primaryimage",
                    "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png",
                    "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/07\/late-stage-failure-in-oncology-4-3-ratio.png",
                    "width": 1448,
                    "height": 1086
                },
                {
                    "@type": "BreadcrumbList",
                    "@id": "https:\/\/www.phinc-group.com\/avoiding-late-stage-failure-in-oncology\/#breadcrumb",
                    "itemListElement": [
                        {
                            "@type": "ListItem",
                            "position": 1,
                            "name": "Accueil",
                            "item": "https:\/\/www.phinc-group.com\/en\/"
                        },
                        {
                            "@type": "ListItem",
                            "position": 2,
                            "name": "Eviter les \u00e9checs de stade avanc\u00e9 en oncologie"
                        }
                    ]
                },
                {
                    "@type": "WebSite",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#website",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "name": "PhinC Group",
                    "description": "Quantitative Pharmacology Solutions &amp; Modeling",
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "potentialAction": [
                        {
                            "@type": "SearchAction",
                            "target": {
                                "@type": "EntryPoint",
                                "urlTemplate": "https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"
                            },
                            "query-input": {
                                "@type": "PropertyValueSpecification",
                                "valueRequired": true,
                                "valueName": "search_term_string"
                            }
                        }
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "Organization",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#organization",
                    "name": "PhinC Group",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "logo": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/",
                        "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "width": 600,
                        "height": 600,
                        "caption": "PhinC Group"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"
                    }
                },
                {
                    "@type": "Person",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a",
                    "name": "Mohamed Taourirt",
                    "image": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "url": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "contentUrl": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "caption": "Mohamed Taourirt"
                    },
                    "url": "https:\/\/www.phinc-group.com\/fr\/author\/mtaourirt\/"
                }
            ]
        }
    },
    "_links": {
        "self": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5110",
                "targetHints": {
                    "allow": [
                        "GET"
                    ]
                }
            }
        ],
        "collection": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts"
            }
        ],
        "about": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/types\/post"
            }
        ],
        "author": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/users\/2"
            }
        ],
        "replies": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/comments?post=5110"
            }
        ],
        "version-history": [
            {
                "count": 17,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5110\/revisions"
            }
        ],
        "predecessor-version": [
            {
                "id": 5129,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5110\/revisions\/5129"
            }
        ],
        "wp:featuredmedia": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media\/5109"
            }
        ],
        "wp:attachment": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media?parent=5110"
            }
        ],
        "wp:term": [
            {
                "taxonomy": "category",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/categories?post=5110"
            },
            {
                "taxonomy": "post_tag",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/tags?post=5110"
            },
            {
                "taxonomy": "service-associe",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/service-associe?post=5110"
            }
        ],
        "curies": [
            {
                "name": "wp",
                "href": "https:\/\/api.w.org\/{rel}",
                "templated": true
            }
        ]
    }
}